Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementBlue Cross MA Neuromodulation Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - MassachusettsPolicy 255

    Audio-Visual Neuromodulation for Neuropathic Pain

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 255 alerts

    Get alerted when Policy 255 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs FDA-authorized prescription audiovisual digital therapeutics using dedicated wearable hardware and software to treat neuropathic pain, including chronic lower back pain. The service is considered investigational for commercial and Medicare Blue members and is not covered where the policy-specific outpatient determination applies.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyAudio-Visual Neuromodulation for Neuropathic Pain
    Policy CodePolicy 255
    Change TypeNew policy
    Effective DateOctober 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionPrecertification or preauthorization is required when the service described in this policy is performed inpatient.
    SourceLink
    POLICY UPDATE CHANGES

    A new medical policy was created stating that FDA-authorized prescription audiovisual digital therapeutics for neuropathic pain are investigational.

    InvestigationalCoverage determination
    N=75Pivotal trial participants
    67% vs 32%Responder rate: active vs sham

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Jan 2026
    FDA authorization date
    NoneSpecific CPT codes

    Coverage Criteria

    Products Within Policy Scope

    Products are within the scope of this review when ALL of the following criteria are met:

    ALL of the following

    • The product is a prescription virtual reality or audiovisual digital therapeutic for management of chronic lower back pain or neuropathic pain.
    • The product is a digital therapeutic in which software performs one or more medical purposes as the primary therapeutic component of an integrated hardware-software system.
    • The product delivers its primary therapeutic effect through integrated audiovisual hardware, including a dedicated wearable audiovisual stimulation device.
    • The product has received U.S. Food and Drug Administration (FDA) marketing clearance, authorization, or approval, including De Novo classification or 510(k) clearance as applicable.
    • The product is prescribed by a healthcare provider.

    Technology Evaluation Standards

    FDA-authorized prescription digital therapeutics must satisfy ALL of the following technology evaluation standards:

    ALL of the following

    • The technology has final approval from the appropriate governmental regulatory bodies.
    • The scientific evidence permits conclusions concerning the effect of the technology on health outcomes.
    • The technology improves the net health outcome.

      The technology must assure protection of sensitive patient health information in accordance with the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).

    • The technology is as beneficial as any established alternatives.
    • The improvement is attainable outside investigational settings.

    Investigational Indication

    The use of U.S. Food and Drug Administration-authorized prescription audiovisual digital therapeutics for neuropathic pain is considered investigational.

    Prescription audiovisual digital therapeutics for neuropathic pain are investigational.

    Software used solely to store or transmit medical information is excluded from the definition of a prescription digital therapeutic within the scope of this policy and is not included in this review.

    Software-only digital therapeutics without integrated dedicated audiovisual hardware, including a wearable audiovisual stimulation device through which proprietary software delivers the primary therapeutic intervention, are excluded from this review.

    The technology is considered investigational because the evidence is insufficient to determine that it improves the net health outcome. Evidence for the Sana Device consists of a single pivotal double-blind, sham-controlled randomized trial (N=75). Although the prespecified week-14 primary endpoint was met and the active group had a higher responder rate and reduced use of multiple pain medication classes, both groups improved at week 10, no significant between-group differences were observed for mood, anxiety, sleep quality, or quality of life, and the evidence has not been independently replicated. Limitations include use of an externally unvalidated MCID derived from the same trial data, baseline imbalances in key prognostic variables that were not controlled in the primary model, and uncertainty regarding the durability of neuroplastic changes, the need for repeated treatment cycles, and appropriate retreatment intervals. Moving from investigational status to a determination of improved net health outcome would require, at minimum, independent replication with prognostic variables controlled as covariates, a prospectively established MCID derived from an external cohort independent of the pivotal trial, and controlled follow-up of at least 6 to 12 months to establish durability of effect.

    Coding Information

    CPT CodesCPT
    No codes listed

    Provider and Authorization Requirements

    Prior Authorization

    Inpatient Prior Authorization Required

    Precertification/preauthorization is required for all products when a service described in this policy is performed on an inpatient basis.

    • Applies to all products.
    • Obtain inpatient authorization before the procedure.],
    Documentation Required

    Product Eligibility and Prescription Documentation

    Confirm that the product meets the policy's eligibility and documentation requirements before requesting coverage. The product must be a prescription digital therapeutic in which software is the primary therapeutic component of an integrated hardware-software system, have FDA marketing authorization, and be prescribed by a healthcare provider.

    • Dedicated wearable audiovisual hardware is required; software-only products and software used solely to store or transmit medical information are outside scope.

    Policy Background

    This policy evaluates prescription digital therapeutics for neuropathic pain, including chronic lower back pain, that deliver their primary therapeutic effect through an integrated hardware-software system. Unlike software-only products, these therapies require dedicated wearable audiovisual stimulation hardware and proprietary software to deliver the primary therapeutic intervention. Products within scope must be FDA-authorized and prescribed by a healthcare provider.

    Definitions

    Prescription digital therapeutic (PDT)
    Primary therapeutic componentSoftware that performs one or more medical purposes as the primary therapeutic component of a hardware-software system.
    System requirementThe software is part of a hardware-software system.
    ExclusionSoftware used solely to store or transmit medical information is excluded.
    Audiovisual digital therapeutic
    Therapeutic typeA prescription digital therapeutic that delivers its primary therapeutic effect through an integrated hardware-software system.
    Stimulation methodThe system uses immersive visual or audiovisual stimulation.

    Not Covered Services

    FDA-authorized prescription audiovisual digital therapeutics for neuropathic pain are not covered because their use is considered investigational; current evidence is insufficient to determine that they improve net health outcomes. Software-only digital therapeutics, and software used solely to store or transmit medical information, are outside the specific scope of this policy.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyAudio-Visual Neuromodulation for Neuropathic Pain
    Policy CodePolicy 255
    Change TypeNew policy
    Effective DateOctober 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionPrecertification or preauthorization is required when the service described in this policy is performed inpatient.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider and Authorization RequirementsPolicy BackgroundDefinitionsNot Covered Services

    The technology must demonstrate usability in a real-world setting.

  1. FDA authorization may include De Novo classification or 510(k) clearance.
  2. Document the healthcare provider's prescription.],
  3. Denial Risk

    Investigational Service

    The use of FDA-authorized prescription audiovisual digital therapeutics for neuropathic pain is considered investigational. The available evidence is insufficient to determine that these technologies improve the net health outcome.

    • This determination applies to Commercial Managed Care, Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM members.
    • The evidence is limited to a single pivotal trial without independent replication and lacks adequate long-term durability data.],

    Unsupported block type: denial_risk

    Unsupported block type: prior_auth

    Denial Risk

    Investigational Audiovisual Digital Therapeutics

    FDA-authorized prescription audiovisual digital therapeutics for neuropathic pain remain investigational under this policy, including products that have received FDA authorization and are prescribed for use with dedicated audiovisual hardware.

    • The policy was effective October 1, 2026.
    • FDA authorization alone does not establish coverage.
    Hardware requirement
    The system requires dedicated wearable audiovisual stimulation hardware; software-only products are not included.